Open AccessComparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
Author(s) -
Firas S. Ahmed,
Laurent Dercle,
Gregory V. Goldmacher,
Hao Yang,
Dana E. Connors,
Ying Tang,
Sanja Karovic,
Binsheng Zhao,
Richard D. Carvajal,
Caroline Robert,
Michael L. Maitland,
Geoffrey R. Oxnard,
Lawrence H. Schwartz
Publication year - 2020
Publication title -
european radiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.606
H-Index - 149
eISSN - 1432-1084
pISSN - 0938-7994
DOI - 10.1007/s00330-020-07249-y
Subject(s) - medicine , pembrolizumab , response evaluation criteria in solid tumors , clinical trial , radiology , oncology , nuclear medicine , immunotherapy , phases of clinical research , cancer
To compare tumor best overall response (BOR) by RECIST 1.1 and iRECIST, to explore the incidence of pseudoprogression in melanoma treated with pembrolizumab, and to assess the impact of pseudoprogression on overall survival (OS).